AIM: To investigate the effects of a ghrelin receptor agonist GHRP-6 on delayed gastrointestinal transit in alloxan-induced diabetic mice. METHODS: A diabetic mouse model was established by intraperitoneal injection with alloxan. Mice were randomized into two main groups: normal mice and diabetic mice treated with GHRP-6 at doses of 0, 20, 50, 100 and 200 microg/kg ip. Gastric emptying (GE), intestinal transit (IT), and colonic transit (CT) were studied in mice after they had a phenol red meal following injection of GHRP-6. Based on the most effective GHRP-6 dosage, atropine was given at 1 mg/kg for 15 min before the GHRP-6 injection for each measurement. The mice in each group were sacrificed 20 min later and the percentages of GE, IT, and CT were calculated. RESULTS: Percentages of GE, IT, and CT were significantly decreased in diabetic mice as compared to control mice. In the diabetic mice, GHRP-6 improved both GE and IT, but not CT. The most effective dose of GHRP-6 was 200 microg/kg and atropine blocked the prokinetic effects of GHRP-6 on GE and IT. CONCLUSION: GHRP-6 accelerates delayed GE and IT, but has no effect on CT in diabetic mice. GHRP-6 may exert its prokinetic effects via the cholinergic pathway in the enteric nervous system, and therefore, has therapeutic potential for diabetic patients with delayed upper gastrointestinal transit.
AIM: To investigate the effects of a ghrelin receptor agonist GHRP-6 on delayed gastrointestinal transit in alloxan-induced diabeticmice. METHODS: A diabeticmouse model was established by intraperitoneal injection with alloxan. Mice were randomized into two main groups: normal mice and diabeticmice treated with GHRP-6 at doses of 0, 20, 50, 100 and 200 microg/kg ip. Gastric emptying (GE), intestinal transit (IT), and colonic transit (CT) were studied in mice after they had a phenol red meal following injection of GHRP-6. Based on the most effective GHRP-6 dosage, atropine was given at 1 mg/kg for 15 min before the GHRP-6 injection for each measurement. The mice in each group were sacrificed 20 min later and the percentages of GE, IT, and CT were calculated. RESULTS: Percentages of GE, IT, and CT were significantly decreased in diabeticmice as compared to control mice. In the diabeticmice, GHRP-6 improved both GE and IT, but not CT. The most effective dose of GHRP-6 was 200 microg/kg and atropine blocked the prokinetic effects of GHRP-6 on GE and IT. CONCLUSION:GHRP-6 accelerates delayed GE and IT, but has no effect on CT in diabeticmice. GHRP-6 may exert its prokinetic effects via the cholinergic pathway in the enteric nervous system, and therefore, has therapeutic potential for diabeticpatients with delayed upper gastrointestinal transit.
Authors: M Shintani; Y Ogawa; K Ebihara; M Aizawa-Abe; F Miyanaga; K Takaya; T Hayashi; G Inoue; K Hosoda; M Kojima; K Kangawa; K Nakao Journal: Diabetes Date: 2001-02 Impact factor: 9.461
Authors: A Asakawa; A Inui; T Kaga; H Yuzuriha; T Nagata; N Ueno; S Makino; M Fujimiya; A Niijima; M A Fujino; M Kasuga Journal: Gastroenterology Date: 2001-02 Impact factor: 22.682
Authors: H S Sallam; H M Oliveira; H T Gan; D N Herndon; J D Z Chen Journal: Am J Physiol Regul Integr Comp Physiol Date: 2006-09-07 Impact factor: 3.619
Authors: A M Wren; C J Small; H L Ward; K G Murphy; C L Dakin; S Taheri; A R Kennedy; G H Roberts; D G Morgan; M A Ghatei; S R Bloom Journal: Endocrinology Date: 2000-11 Impact factor: 4.736
Authors: Anwarbaig C Mirza; Shital S Panchal; Ahmed A Allam; Sarah I Othman; Milan Satia; Sanjay N Mandhane Journal: Molecules Date: 2022-10-09 Impact factor: 4.927